The impact of the presence of antithyroid antibodies on pregnancy outcome following intracytoplasmatic sperm injection-ICSI and embryo transfer in women with normal thyreotropine levels.

PURPOSE: The aim of our study was to investigate the impact of anti-thyroid peroxidase antibodies (Anti-TPO) on pregnancy outcome following the in vitro fertilization and embryo transfer (IVF-ET) in general groups and in subgroups divided according to AMH level and age. METHODS: A total of 114 patients positive for anti-thyroid peroxidase antibodies (Anti-TPO+ group) and 495 infertile women negative for anti-thyroid peroxidase antibodies (Anti-TPO- group) undergoing IVF with ICSI from April 2010 to April 2012 were analyzed retrospectively. RESULTS: There were no significant differences in age, BMI, basal FSH, LH, AMH levels and duration of infertility between the two main groups. No significant differences in terms of the days of ovarian stimulation, estradiol level in day 8, total gonadotropin dose, number of oocytes retrieved, available embryos and blastocysts, number of embryos transferred nor in rates of fertilization, implantation, clinical pregnancy, live birth and abortion rate between two main groups were found. The only statistically significant difference among the groups with different anti-TPO antibodies levels was found in basal FSH concentration and BMI. Among the clinical outcomes of IVF with respect to the different anti-TPO levels, the only significant difference was found for the number of oocytes retrieved. Analysis of the baseline parameters in relationship to age categories and AMH levels found significant differences between women positive and negative for thyroid antibodies with respect to basal FSH and LH levels for women >37 years and for basal FSH in AMH <0.6 subgroup. CONCLUSIONS: The present study reveals that patients with anti-TPO antibodies showed no significant differences in fertilization, implantation, pregnancy rates, live birth rates and no higher risk for miscarriage following IVF-ET when compared with those negative for anti-thyroid antibodies.

Evaluation of Livingston's chemotherapy combined with immunotherapy in treatment of small cell lung carcinoma.

The comparative studies presented in this work aimed at evaluation of isoprinosine in the combined cytostatic and irradiation treatment of small cell lung cancer. The comparison was performed between three groups of patients: 1. treated by the method of Livingston et al., 2. treated by the method of Livingston et al. in a combination with isoprinosine, 3. treated by the same method but the cycle of treatment was shortened from 3 weeks to 8 days with the parallel application of isoprinosine as immunotherapeutic and stimulator of the hematopoietic system. It was found that the mean time of complete and partial remission and the mean survival time was longer in the second and third group of patients. The mean survival time in the first group amounted to 3 weeks, in the second to 43 weeks and in the third to 49 weeks. It was also shown that post-chemotherapy complications were less frequent and less intensive.